Literature DB >> 8830282

Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation.

K Weissenborn1, C Ehrenheim, A Hori, S Kubicka, M P Manns.   

Abstract

Fifty patients with liver cirrhosis underwent neurological, psychometric, electroencephalographic and biochemical examination as well as cranial magnetic resonance imaging (MRI) to study the incidence of pallidal lesions in cirrhotics and their correlation to liver function, as well as to neurological and mental state. In one patient a histopathological study of the brain was performed. The vast majority of the patients with liver cirrhosis (92%) present with bilateral symmetric pallidal hyperintensities in the T1-weighted MR spin echo sequence, while the T2-weighted images are normal. On the whole there was no correlation between the signal intensity of the pallidal lesions and measures of liver function, neurological status or grade of encephalopathy. As could be shown in follow-up examinations the signal intensity of the lesions increased with decreasing liver function and decreased with normalization of liver function after liver transplantation. The substrate of the lesions remains unclear. However, regions which show alterations in the MRI are histopathologically characterized by the appearance of Alzheimer-type-II cells.

Entities:  

Mesh:

Year:  1995        PMID: 8830282     DOI: 10.1007/bf02081027

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  20 in total

1.  MR imaging of acquired hepatocerebral degeneration.

Authors:  J Kulisevsky; J Ruscalleda; J M Grau
Journal:  AJNR Am J Neuroradiol       Date:  1991 May-Jun       Impact factor: 3.825

2.  Case report--MR imaging of chronic persistent hepatic encephalopathy.

Authors:  A Uchino; T Miyoshi; M Ohno
Journal:  Radiat Med       Date:  1989 Nov-Dec

3.  Hyperintensity in the globus pallidus on T1-weighted and inversion-recovery MRI: a possible marker of advanced liver disease.

Authors:  A Pujol; F Graus; J Peri; J M Mercader; A Rimola
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

4.  Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition.

Authors:  S A Mirowitz; T J Westrich; J D Hirsch
Journal:  Radiology       Date:  1991-10       Impact factor: 11.105

5.  Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. A controlled study.

Authors:  J W Moore; A A Dunk; J R Crawford; H Deans; J A Besson; G De Lacey; T S Sinclair; N A Mowat; P W Brunt
Journal:  J Hepatol       Date:  1989-11       Impact factor: 25.083

6.  Increased manganese concentrations in pallidum of cirrhotic patients.

Authors:  G Pomier-Layrargues; L Spahr; R F Butterworth
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

7.  Visualizing manganese in the primate basal ganglia with magnetic resonance imaging.

Authors:  M C Newland; T L Ceckler; J H Kordower; B Weiss
Journal:  Exp Neurol       Date:  1989-12       Impact factor: 5.330

8.  Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T.

Authors:  J A Brunberg; E Kanal; W Hirsch; D H Van Thiel
Journal:  AJNR Am J Neuroradiol       Date:  1991 Sep-Oct       Impact factor: 3.825

9.  MRI pallidal hyperintensity and brain atrophy in cirrhotic patients: two different MRI patterns of clinical deterioration?

Authors:  J Kulisevsky; J Pujol; C Junqué; J Deus; J Balanzó; A Capdevila
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

10.  Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: clinical correlations.

Authors:  J Kulisevsky; J Pujol; J Balanzó; C Junqué; J Deus; A Capdevilla; C Villanueva
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

View more
  27 in total

Review 1.  Cerebral magnetic resonance imaging in patients with chronic liver disease.

Authors:  M Y Morgan
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Role of manganese in the pathogenesis of portal-systemic encephalopathy.

Authors:  G P Layrargues; C Rose; L Spahr; J Zayed; L Normandin; R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 3.  Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 4.  The basal ganglia and portal-systemic encephalopathy.

Authors:  K Weissenborn; H Kolbe
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

5.  Quantitative magnetic resonance imaging in patients with cirrhosis: a cross-sectional study.

Authors:  Vijay P B Grover; Mary M E Crossey; Julie A Fitzpatrick; Brian K Saxby; Roberta Shaw; Adam D Waldman; Marsha Y Morgan; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2015-08-08       Impact factor: 3.584

Review 6.  Functional imaging of the brain in patients with liver cirrhosis.

Authors:  Karin Weissenborn; Martin Bokemeyer; Björn Ahl; Daniela Fischer-Wasels; Kathrin Giewekemeyer; Jörg van den Hoff; Herbert Köstler; Georg Berding
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 7.  Hepatic encephalopathy: a dynamic or static condition.

Authors:  Charmaine A Stewart; Jane Cerhan
Journal:  Metab Brain Dis       Date:  2005-09       Impact factor: 3.584

Review 8.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

Review 9.  MR imaging findings in hepatic encephalopathy.

Authors:  A Rovira; J Alonso; J Córdoba
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

10.  Accumulation of manganese and copper in pallidum of cirrhotic patients: role in the pathogenesis of hepatic encephalopathy?

Authors:  G P Layrargues; D Shapcott; L Spahr; R F Butterworth
Journal:  Metab Brain Dis       Date:  1995-12       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.